Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 11/20 | 0.47 |
| ▸ | DDB1 | Q16531 | 9/20 | 0.47 |
| ▸ | STAT3 | P40763 | 5/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.42 |
| ▸ | HDAC2 | Q92769 | 4/20 | 0.42 |
| ▸ | HDAC3 | O15379 | 3/20 | 0.42 |
| ▸ | NCOR2 | Q9Y618 | 3/20 | 0.42 |
| ▸ | CA2 | P00918 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23915176 | 0.92 | CRBN (0.46) | CRBNDDB1STAT3HDAC1HDAC2 | |
| SCHEMBL24671633 | 0.91 | STAT3 (0.47) | CRBNDDB1STAT3HDAC1CA2 | |
| SCHEMBL24671771 | 0.90 | STAT3 (0.48) | CRBNDDB1STAT3HDAC1CA2 | |
| SCHEMBL24979657 | 0.90 | STAT3 (0.48) | CRBNDDB1STAT3HDAC1CA2 | |
| SCHEMBL23915135 | 0.88 | CRBN (0.46) | CRBNDDB1STAT3HDAC1HDAC2 | |
| SCHEMBL23946161 | 0.86 | STAT3 (0.48) | CRBNDDB1STAT3CA2 | |
| SCHEMBL23915301 | 0.85 | HDAC1 (0.47) | CRBNDDB1STAT3HDAC1HDAC2 | |
| SCHEMBL24745278 | 0.84 | STAT3 (0.49) | CRBNDDB1STAT3HDAC1HDAC2 | |
| SCHEMBL25894250 | 0.84 | CRBN (0.44) | CRBNDDB1STAT3HDAC1HDAC2 | |
| SCHEMBL23945868 | 0.83 | CRBN (0.48) | CRBNDDB1STAT3HDAC1HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210315999-A1 | TROPOMYOSIN RECEPTOR KINASE (TRK) DEGRADATION COMPOUNDS AND METHODS OF USE | CULLGEN (SHANGHAI), INC. (CN) | 2021-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210315999-A1 | TROPOMYOSIN RECEPTOR KINASE (TRK) DEGRADATION COMPOUNDS AND METHODS OF USE | MUSK, ERBB2, NTRK1 | CRBN 330/4885DDB1 480/4885STAT3 3381/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.